NASH Therapeutic Drugs Market - Global Industry Research Analysis

NASH Therapeutic Drugs Market Insights

According to Market Research Store, the global NASH therapeutic drugs market size was valued at around USD 5.18 billion in 2023 and is estimated to reach USD 20.26 billion by 2032, to register a CAGR of approximately 16.35% in terms of revenue during the forecast period 2024-2032.

The NASH therapeutic drugs report provides a comprehensive analysis of the market, including its size, share, growth trends, revenue details, and other crucial information regarding the target market. It also covers the drivers, restraints, opportunities, and challenges till 2032.

To Get more Insights, Request a Free Sample

Global NASH Therapeutic Drugs Market: Overview

NASH (Non-Alcoholic Steatohepatitis) therapeutic drugs are medications designed to treat NASH, a progressive form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation and damage due to fat accumulation. These drugs aim to reduce liver fibrosis, inflammation, and fat buildup, ultimately preventing cirrhosis and liver failure. Current treatment approaches include anti-fibrotic agents, metabolic regulators, and anti-inflammatory drugs, with various candidates in clinical trials targeting different disease mechanisms.

Key Highlights

• The NASH therapeutic drugs market is anticipated to grow at a CAGR of 16.35% during the forecast period.
• The global NASH therapeutic drugs market was estimated to be worth approximately USD 5.18 billion in 2023 and is projected to reach a value of USD 20.26 billion by 2032.
• The growth of the NASH therapeutic drugs market is being driven by rising prevalence of obesity, type 2 diabetes, and metabolic syndrome—key risk factors for the disease.
• Based on the type, the vitamin e & pioglitazone segment is growing at a high rate and is projected to dominate the market.
• On the basis of application, the hospital pharmacy segment is projected to swipe the largest market share.
• By region, North America is expected to dominate the global market during the forecast period.

NASH Therapeutic Drugs Market: Dynamics

Key Growth Drivers:

• Rising prevalence of NASH: The increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome, all risk factors for NASH, is driving the demand for effective treatments.
• Lack of approved therapies: Currently, there are limited approved drugs specifically for NASH, creating a significant unmet medical need and a huge market opportunity.
• Growing awareness and diagnosis: Increased awareness of NASH among healthcare professionals and patients is leading to earlier diagnosis and a larger pool of potential treatment candidates.
• Strong pipeline of drug candidates: Numerous pharmaceutical companies are investing heavily in developing NASH therapies, with a robust pipeline of drug candidates in various stages of clinical trials.

Restraints:

• Complex pathophysiology: NASH is a complex disease with multiple contributing factors, making it challenging to develop effective therapies that target all aspects of the disease.
• Difficulties in diagnosis: NASH is often asymptomatic in its early stages, and diagnosis typically requires invasive liver biopsies, which can limit patient willingness to undergo testing.
• Regulatory hurdles: The regulatory pathway for NASH drugs is complex, with stringent requirements for demonstrating efficacy and safety, which can delay or hinder drug approvals.
• High cost of drug development: Developing NASH therapies is expensive due to the need for extensive clinical trials and research, which can impact drug pricing and market access.

Opportunities:

• Development of non-invasive diagnostics: The development of non-invasive diagnostic tools, such as blood tests or imaging techniques, could significantly improve early detection and patient access to treatment.
• Personalized medicine: Tailoring treatment approaches based on individual patient characteristics and disease stage could improve treatment outcomes and expand the market for NASH therapies.
• Combination therapies: Combining different drugs that target multiple pathways involved in NASH pathogenesis could offer more effective treatment options.
• Growing market in emerging economies: The increasing prevalence of NASH in emerging economies presents significant growth opportunities for pharmaceutical companies.

Challenges:

• Clinical trial design: Designing and conducting clinical trials for NASH drugs is challenging due to the need for appropriate patient selection, relevant endpoints, and long study durations.
• Demonstrating long-term efficacy: Demonstrating the long-term efficacy and safety of NASH therapies is crucial for regulatory approvals and market acceptance.
• Competition: The NASH market is becoming increasingly competitive, with numerous companies vying to develop and commercialize their therapies.
• Reimbursement and market access: Securing adequate reimbursement and market access for NASH drugs can be challenging due to the high cost of these therapies and the need to demonstrate their value to payers.

NASH Therapeutic Drugs Market: Report Scope

NASH Therapeutic Drugs Market: Segmentation Insights

The global NASH therapeutic drugs market is divided by type, application, and region.

Segmentation Insights by Type

Based on type, the global NASH therapeutic drugs market is divided into vitamin e & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc.

The Vitamin E & Pioglitazone segment is the most dominant in the NASH (Non-Alcoholic Steatohepatitis) therapeutic drugs market. Vitamin E, a powerful antioxidant, is widely used to reduce oxidative stress and inflammation in NASH patients, particularly those without diabetes. Pioglitazone, a thiazolidinedione, improves insulin sensitivity and reduces liver fat accumulation, making it a commonly prescribed off-label treatment for NASH. Due to their availability, affordability, and established efficacy in improving liver histology, these drugs continue to be the primary treatment option despite the absence of FDA-approved medications specifically for NASH.

Ocaliva (Obeticholic Acid) follows as the second most dominant segment. It is a semi-synthetic bile acid derivative and FXR (Farnesoid X Receptor) agonist that plays a crucial role in reducing liver fibrosis and inflammation. Ocaliva received conditional FDA approval for primary biliary cholangitis and has shown promising results in clinical trials for NASH treatment. Its growing adoption in patients with significant fibrosis makes it a key player in the market, though its high cost and potential side effects, including pruritus and increased cholesterol levels, have limited its widespread use.

Elafibranor is the next in line, being a dual PPAR (Peroxisome Proliferator-Activated Receptor) alpha/delta agonist designed to target lipid metabolism, inflammation, and fibrosis in NASH patients. Despite its promising mechanism of action, Elafibranor has faced challenges in clinical trials, including mixed efficacy results, which have slowed its commercial uptake. However, ongoing research and potential combination therapies may increase its market presence in the future.

At the bottom of the market segmentation are Selonsertib & Cenicriviroc, both of which have struggled to gain traction due to disappointing clinical trial outcomes. Selonsertib, an ASK1 (Apoptosis Signal-Regulating Kinase 1) inhibitor, failed to show significant fibrosis reduction in late-stage trials. Similarly, Cenicriviroc, a CCR2/CCR5 antagonist, showed modest improvements in fibrosis but did not meet expectations for efficacy. As a result, these drugs have seen limited adoption, positioning them as the least dominant segment in the NASH therapeutic drugs market.

Segmentation Insights by Application

On the basis of application, the global NASH therapeutic drugs market is bifurcated into hospital pharmacy, online provider, and retail pharmacy.

The Hospital Pharmacy segment is the most dominant in the NASH therapeutic drugs market. Hospitals are the primary centers for diagnosing and managing advanced cases of NASH, particularly for patients with significant fibrosis or cirrhosis. Due to the complexity of the disease, specialists such as hepatologists and gastroenterologists typically prescribe and monitor NASH treatments in hospital settings. Additionally, hospitals have access to the latest clinical guidelines and emerging therapies, making them the key distribution channel for advanced and prescription-based NASH medications.

Retail Pharmacy follows as the second most dominant segment, serving as a convenient and accessible distribution channel for patients requiring long-term NASH management. Commonly used treatments such as Vitamin E and Pioglitazone are readily available in retail pharmacies, making them an essential component of the market. Additionally, retail pharmacies provide over-the-counter supplements and lifestyle modification products that complement NASH treatments, further boosting their market share. However, their role in distributing newly approved or specialized NASH drugs is limited compared to hospital pharmacies.

The Online Provider segment is the least dominant but is experiencing steady growth. With the increasing adoption of telemedicine and e-commerce in healthcare, online pharmacies provide an alternative way for patients to access NASH medications. The convenience of home delivery and potential cost savings through online discounts are attractive factors driving the segment's growth. However, regulatory challenges, prescription verification issues, and patient preference for in-person consultations currently limit the dominance of online providers in the NASH therapeutic drugs market.

NASH Therapeutic Drugs Market: Regional Insights

• North America is expected to dominates the global market

North America currently leads the NASH therapeutic drugs market, primarily due to a high prevalence of non-alcoholic steatohepatitis, advanced healthcare infrastructure, and significant investment in research and development. The United States, in particular, has a substantial patient population affected by NASH, driven by rising rates of obesity and type 2 diabetes. The presence of key pharmaceutical companies actively engaged in developing novel NASH treatments further bolsters the region's dominance. Additionally, increased awareness and early diagnosis contribute to the robust demand for therapeutic interventions in this region.

Europe holds a significant share in the NASH therapeutic drugs market, supported by a well-established healthcare system and growing awareness of liver diseases. Countries such as Germany, France, and the United Kingdom are at the forefront, with increasing investments in healthcare research and a rising prevalence of metabolic disorders contributing to NASH cases. The region's focus on early diagnosis and intervention, along with supportive government initiatives, enhances the adoption of emerging NASH therapies.

The Asia-Pacific region is experiencing rapid growth in the NASH therapeutic drugs market, driven by increasing prevalence of obesity and diabetes, which are major risk factors for NASH. Countries like China, India, and Japan are witnessing a surge in NASH cases due to lifestyle changes and dietary habits. Improving healthcare infrastructure, rising healthcare expenditures, and growing awareness about liver health are facilitating greater access to diagnostics and treatments, positioning the region as a significant contributor to market expansion.

Latin America is emerging as a potential market for NASH therapeutic drugs, with countries such as Brazil and Argentina experiencing a rise in NASH prevalence linked to increasing rates of obesity and metabolic syndrome. While the healthcare infrastructure in these countries is still developing, there is a growing focus on improving healthcare access and investing in medical research. Government initiatives aimed at addressing non-communicable diseases are expected to support the adoption of NASH therapies in the coming years.

The Middle East and Africa region currently hold a smaller share in the NASH therapeutic drugs market, primarily due to limited healthcare infrastructure and lower awareness levels. However, increasing urbanization and lifestyle changes are leading to higher incidences of obesity and diabetes, contributing to a growing NASH burden. Efforts to enhance healthcare services, coupled with initiatives to raise awareness about liver diseases, are anticipated to gradually improve the uptake of NASH treatments in this region.

Recent Developments:

• In May 2024, the FDA approved Rezdiffra (resmetirom) by Madrigal Pharmaceuticals for adults with noncirrhotic NASH and moderate to advanced liver fibrosis. It is used alongside diet and exercise.
• In June 2022, Novo Nordisk and Echosens partnered to improve NASH diagnosis through non-invasive solutions, aiming to double detection rates by 2025 and unlock new market opportunities.

NASH Therapeutic Drugs Market: Competitive Landscape

The report provides an in-depth analysis of companies operating in the NASH therapeutic drugs market, including their geographic presence, business strategies, product offerings, market share, and recent developments. This analysis helps to understand market competition.

Some of the major players in the global NASH therapeutic drugs market include:

• Allergan Plc (Tobira)
• Bristol Myers Squibb
• Galmed Pharmaceuticals
• Genfit SA
• Intercept Pharmaceuticals Inc.
• Zydus Cadila
• Inventiva
• AbbVie Inc.
• Galectin Therapeutics Inc.
• Madrigal Pharmaceuticals Inc (Madrigal)
• NGM Biopharmaceuticals, Inc.
• Novo Nordisk A/S
• Gilead Sciences Inc.

The global NASH therapeutic drugs market is segmented as follows:

By Type

• Vitamin E and Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib and Cenicriviroc

By Application

• Hospital Pharmacy
• Online Provider
• Retail Pharmacy

By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • France
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• The Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East Africa

Frequently Asked Questions